DexCom Inc (DXCM) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Total Revenue Chart for DexCom Inc
DexCom Inc (DXCM) revenue for FY2025 was USD 4.7B, a 15.6% change from FY2024. DexCom Inc's revenue grew from USD 2.2M in 2006 to USD 4.7B in 2025 (214759.5% over 19 years). Earnings per share moved from USD -0.17 in 2011 to USD 0.80 in 2022. Revenue compound annual growth rate: 5-year CAGR of 19.3%, 10-year CAGR of 27.8%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $31.19B
- Implied Share Price
- $82.66
- Enterprise Value
- $32.26B
- Revenue (TTM)
- $4.97B
- EBITDA
- $1.40B
- Profit Margin
- 20.12%
- Trailing P/E
- 32.67
- Forward P/E
- 34.36
- Price/Book (MRQ)
- 12.52
- Price/Sales (TTM)
- 6.30
- EV/EBITDA
- 20.69
- EV/Revenue
- 6.49
- Dividend Yield
- —
- Book Value
- $6.95
- Free Cash Flow (FY2025)
- $1.08B
- Free Cash Flow Yield
- 3.45%
Snapshot as of 5th August 2026 — not point-in-time controlled, may lag the live market by a few days.